No Phase 1 Filed. Irisin Delivers Anyway.
The Peptide Market's Missing IND
The grey-market peptide injection trend is a clinical trial without a principal investigator, an IRB, or a dose-response curve. BPC-157 (a synthetic pentadecapeptide studied in rat gastric ulcer and tendon repair models since the 1990s) and growth hormone secretagogues (ipamorelin and CJC-1295) are sourced through grey-market suppliers in Singapore, Hong Kong, and Sydney. Neither compound has a Phase 1 dose-escalation study in humans filed with any APAC regulatory body. Singapore's Health Sciences Authority (HSA), which requires pre-market registration for therapeutic goods before legal sale, has not approved these compounds for self-administration. Australia's TGA (Therapeutic Goods Administration, the federal body that assesses medicines for safety, quality, and efficacy) has scheduled several BPC-157 formulations under Appendix C of the Poisons Standard, requiring a prescription pathway the grey-market channel does not use. Japan's PMDA (Pharmaceuticals and Medical Devices Agency) has issued no marketing authorisation for any compound in this stack. A buyer in Singapore sourcing these compounds online is running a self-administered dose-escalation study with no sponsor, no data collection, and no adverse-event reporting. The HSA's last synthetic peptide scheduling decision is dated 2023. The supplier network post-dates it.
What the Lifting Data Shows
Irisin, the molecule named in this week's lifting research, is a myokine cleaved from fibronectin type III domain-containing protein 5 (FNDC5) during skeletal muscle contraction and secreted into circulation. The protein was characterized in humans in a 2012 Nature paper by Bostrom et al. and confirmed in human serum by mass spectrometry in subsequent work. Circulating irisin in humans correlates with resistance training volume across multiple large-scale cohort data sets. No injectable irisin formulation has completed Phase 1 in humans. The plasma half-life of circulating irisin in animal models is measured in minutes; sustained systemic elevation through a subcutaneous injection remains a pharmacokinetic problem no grey-market product has addressed. The capital is pricing irisin via the grey-market peptide stack. The resistance training literature has been delivering it since 2012. A person ordering injectable peptides to improve recovery time cannot verify whether their dose falls within a range any human trial has tested. A family-office PM doing due diligence on a peptide company this week should ask whether any Phase 1 filing for irisin delivery exists, and where. The Bostrom et al. characterization is from 2012. Fourteen years of resistance training literature have not produced one.
Singapore's HSA published its synthetic peptide scheduling update in 2023. The grey-market supplier network this injection trend runs on post-dates that update. The HSA's Health Products Regulation Group has announced no follow-on review; no date is on the public calendar. A buyer starting a BPC-157 protocol this month sits outside what the 2023 decision covers. The gap closes when the HSA schedules a review, or when an adverse-event cluster forces one. Neither has a date.